Abivax SA
ABVX117.670USD
+6.960+6.29%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
0.00시가총액
--P/E TTM
자세한 내용은 Abivax SA 회사
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA 정보
종목 코드 ABVX
회사 이름Abivax SA
상장일Jun 26, 2015
CEOde Garidel (Marc)
직원 수- -
유형Depository Receipt
회계 연도 종료- -
주소7-11 Boulevard Haussmann
도시PARIS
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가France
우편 번호75009
전화33153830963
웹사이트https://www.abivax.com/
종목 코드 ABVX
상장일Jun 26, 2015
CEOde Garidel (Marc)
Abivax SA의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mr. Marc de Garidel
Mr. Marc de Garidel
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Dr. June H. Lee, M.D.
Dr. June H. Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Mon, Jan 19
마지막 업데이트: Mon, Jan 19
주주
주주 유형
주주
주주
비율
TCG Crossover Management, LLC
9.67%
UBS Financial Services, Inc.
6.01%
Darwin Global Management Ltd
4.30%
Point72 Asset Management, L.P.
3.98%
Cormorant Asset Management, LP
2.65%
기타
73.39%
주주
주주
비율
TCG Crossover Management, LLC
9.67%
UBS Financial Services, Inc.
6.01%
Darwin Global Management Ltd
4.30%
Point72 Asset Management, L.P.
3.98%
Cormorant Asset Management, LP
2.65%
기타
73.39%
주주 유형
주주
비율
Hedge Fund
33.85%
Investment Advisor
23.62%
Investment Advisor/Hedge Fund
8.93%
Research Firm
2.98%
Venture Capital
2.18%
Private Equity
1.77%
Pension Fund
1.00%
Bank and Trust
0.02%
기타
25.66%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
216
53.64M
52.23%
+104.02K
2025Q3
210
53.54M
52.22%
+19.70M
2025Q2
81
30.74M
57.27%
-1.09M
2025Q1
75
31.82M
50.24%
-38.10K
2024Q4
68
29.91M
44.59%
+2.48M
2024Q3
54
27.43M
45.93%
-700.83K
2024Q2
51
33.52M
46.25%
-227.21K
2024Q1
46
28.78M
34.33%
+7.18M
2023Q4
33
27.04M
1.75%
+20.54M
2023Q3
1
5.40M
0.00%
--
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
TCG Crossover Management, LLC
7.11M
9.67%
+1.05M
+17.42%
Sep 30, 2025
UBS Financial Services, Inc.
4.46M
6.06%
+4.29M
+2560.74%
Sep 30, 2025
Darwin Global Management Ltd
3.16M
4.3%
+3.16M
--
Sep 30, 2025
Point72 Asset Management, L.P.
2.93M
3.98%
+2.76M
+1642.45%
Sep 30, 2025
Cormorant Asset Management, LP
1.95M
2.65%
-180.00K
-8.45%
Sep 30, 2025
Paradigm BioCapital Advisors LP
1.56M
2.13%
+1.56M
--
Sep 30, 2025
Caligan Partners, LP
1.45M
1.97%
-222.48K
-13.29%
Sep 30, 2025
Fidelity Management & Research Company LLC
1.43M
1.94%
+417.90K
+41.26%
Sep 30, 2025
Fred Alger Management, LLC
1.23M
1.67%
+40.31K
+3.38%
Dec 31, 2025
Adar1 Capital Management LLC
1.35M
1.84%
-1.72M
-56.02%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Simplify Health Care ETF
2.86%
Harbor Health Care ETF
0.7%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
0%
Simplify Health Care ETF
비율2.86%
Harbor Health Care ETF
비율0.7%
Fidelity Nasdaq Composite Index ETF
비율0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
비율0%
Innovator IBD Breakout Opportunities ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
